A new trading day began on Friday, with Cue Biopharma Inc (NASDAQ: CUE) stock price up 10.48% from the previous day of trading, before settling in for the closing price of $0.31. CUE’s price has ranged from $0.23 to $1.75 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 15.39% over the past five years. Meanwhile, its annual earnings per share averaged 43.75%. With a float of $90.91 million, this company’s outstanding shares have now reached $91.24 million.
Cue Biopharma Inc (CUE) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cue Biopharma Inc is 0.49%, while institutional ownership is 19.79%. The most recent insider transaction that took place on Dec 30 ’25, was worth 99,747. In this transaction Director of this company bought 323,857 shares at a rate of $0.31, taking the stock ownership to the 323,857 shares. Before that another transaction happened on Dec 29 ’25, when Company’s Officer proposed sale 7,230 for $0.26, making the entire transaction worth $1,907.
Cue Biopharma Inc (CUE) Latest Financial update
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.13 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.19% during the next five years compared to 15.39% growth over the previous five years of trading.
Cue Biopharma Inc (NASDAQ: CUE) Trading Performance Indicators
Here are Cue Biopharma Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.66. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.46, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.47 in one year’s time.
Technical Analysis of Cue Biopharma Inc (CUE)
As of the previous 9 days, the stock’s Stochastic %D was 57.57%.
During the past 100 days, Cue Biopharma Inc’s (CUE) raw stochastic average was set at 14.69%, which indicates a significant decrease from 38.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0482 in the past 14 days, which was lower than the 0.0540 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5534, while its 200-day Moving Average is $0.7123. Nevertheless, the first resistance level for the watch stands at $0.3559 in the near term. At $0.3744, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.4039. If the price goes on to break the first support level at $0.3079, it is likely to go to the next support level at $0.2784. The third support level lies at $0.2599 if the price breaches the second support level.
Cue Biopharma Inc (NASDAQ: CUE) Key Stats
With a market capitalization of 30.78 million, the company has a total of 78,738K Shares Outstanding. Currently, annual sales are 9,290 K while annual income is -40,670 K. The company’s previous quarter sales were 2,150 K while its latest quarter income was -7,450 K.
